Overview

A Study Comparing Continuous Infusion Antibiotics to Standard Treatment for Lung Infections in Cystic Fibrosis

Status:
Unknown status
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
Cystic fibrosis (CF) is an inherited disorder which results in increased thickness of secretions, especially in the lungs. By adulthood, the majority of patients with CF will have a bacteria living in their lungs, called Pseudomonas aeruginosa which can cause lung infections. This usually results in worsening respiratory symptoms and often an acute deterioration in their lung function. They are usually treated with antibiotics that target the Pseudomonas aeruginosa. These antibiotics are typically given as short intravenous infusions several times a day. This study aims to compare the standard method of giving these antibiotics with a different strategy of giving these antibiotics to see if this can improve the outcomes of treatment of these infections and reduce the amount of Pseudomonas aeruginosa in the lungs of these patients. This strategy consists of giving the same antibiotics continuously, to ensure there is always enough antibiotic in the bloodstream and the lung to be able to kill the bacteria.
Phase:
Phase 4
Details
Lead Sponsor:
The Alfred
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Cefepime
Ceftazidime
Cephalosporins
Clavulanic Acid
Clavulanic Acids
Meropenem
Penicillanic Acid
Piperacillin
Piperacillin, Tazobactam Drug Combination
Tazobactam
Thienamycins
Ticarcillin
Ticarcillin-clavulanic acid